Advertisement

Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Document › Details

PharmaMar S.A.. (1/18/18). "Press Release: Pharma Mar, S.A. Announces the Results of the Phase III Clinical Trial (CORAIL) with Zepsyre (lurbinectedin) in Platinum-resistant Ovarian Cancer patients". Colmenar Viejo (Madrid).

Organisation Organisation PharmaMar S.A. (MSE: PHM)
  Group PharmaMar (Group)
Products Product Zepsyre®
  Product 2 clinical research
     


Pursuant to article 228 of the consolidated text of the Spanish Securities Market Act, we hereby inform you of the following SIGNIFICANT EVENT:


“Pharma Mar, S.A. announces the results of the Phase III clinical trial (CORAIL) with Zepsyre® (lurbinectedin) in platinum-resistant ovarian cancer patients.

The CORAIL trial, comparing Zepsyre® versus topotecan or PLD (liposomal doxorubicin) in platinum resistant ovarian cancer patients has not met the primary end-point of the trial, which was PFS (Progression Free Survival).

The antitumoral activity of the three compounds Zepsyre®, topotecan and PLD, in terms of PFS, has been the same. In the CORAIL trial Zepsyre® has demonstrated a better safety profile than the control arm.

Results of this trial will be presented at future oncology congresses.”


Pharma Mar S.A. Avda. de los Reyes, 1 P.I. La Mina 28770 Colmenar Viejo (Madrid) Spain Ph.: +34 91 846 6000 Fax.: +34 91 846 6001 www.pharmamar.com

   
Record changed: 2018-01-25

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for PharmaMar (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC B Preview Download 650x300px




» top